Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ultragenyx Pharmaceutical Affirms FY2025 Sales Guidance of $640.00M-$670.00M vs $653.27M Est

Author: Benzinga Newsdesk | August 05, 2025 03:02pm
Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2025 sales outlook from $640.00 million-$670.00 million to $640.00 million-$670.00 million vs $653.27 million estimate.

Posted In: RARE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist